Black patients are often left out of crucial cancer drug trials
In clinical trials for the majority of FDA-approved cancer drugs, fewer than 5 percent of the patients were black, Stat News and ProPublica reported Wednesday.
Out of the 31 cancer drugs approved since 2015, 24 of them have had single-digit proportions of black patients during trials, the analysis found. In one trial for a multiple myeloma treatment, just 1.8 percent of participants were black, even though black Americans are twice as likely as white Americans to be diagnosed with the blood cancer and there may be "meaningful differences" in how the condition affects the two races.
The Food and Drug Administration has not established any rules that would require drug makers to test treatments on minority patients, and many manufacturers don't diversify their trials voluntarily, reports Stat News.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
Drug companies often say it is challenging to enroll minorities, reports ProPublica. The clinical trials with the highest black participation, up to 12 percent, were from Johnson & Johnson, a company that uses an internal group to improve trial diversity. Advocates have called on the FDA to implement similar standards across the industry, but the agency has demurred.
Minorities are also often not properly incentivized or are not able to participate: Financial barriers, logistical challenges, and distrust of the medical community are all factors that sometimes discourage minorities from joining trials, even though they could be "life-extending opportunities," said Dr. Kashif Ali, research head at Maryland Oncology Hematology. Read more at Stat News.
Create an account with the same email registered to your subscription to unlock access.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Summer Meza has worked at The Week since 2018, serving as a staff writer, a news writer and currently the deputy editor. As a proud news generalist, she edits everything from political punditry and science news to personal finance advice and film reviews. Summer has previously written for Newsweek and the Seattle Post-Intelligencer, covering national politics, transportation and the cannabis industry.
-
Today's political cartoons - October 23, 2024
Cartoons Wednesday's cartoons - loving thy neighbour, an HR matter, and more
By The Week US Published
-
Giuliani must hand assets to women he defamed
Speed Read The former New York City mayor must turn over his apartment and other possessions
By Peter Weber, The Week US Published
-
Abercrombie ex-CEO charged with sex crimes
Speed Read Mike Jeffries ran the brand during its heyday from 1992 to 2014
By Rafi Schwartz, The Week US Published
-
Flame retardants found in black plastics could have health consequences
Under the Radar Time to replace your kitchen tools
By Devika Rao, The Week US Published
-
Preeclampsia: The dangerous pregnancy condition is affecting more women
Under the Radar The condition of preeclampsia is on the rise and can be deadly if left untreated
By Devika Rao, The Week US Published
-
The EEE virus is spreading in the US
The Explainer The mosquito strikes again
By Devika Rao, The Week US Published
-
Baby food is not as healthy as it should be
Under the Radar Labels are leaving things out. And brands are highlighting only what they want to.
By Devika Rao, The Week US Published
-
Why gonorrhoea is becoming 'untreatable'
In the Spotlight Infections hit record high as experts warn about rise in antibiotic-resistant cases
By Elizabeth Carr-Ellis, The Week UK Published
-
Mushroom edibles are tripping up users
the explainer The psychedelics can sometimes have questionable components
By Devika Rao, The Week US Published
-
Brexit, Matt Hancock and black swans: five takeaways from Covid inquiry report
The Explainer UK was 'unprepared' for pandemic and government 'failed' citizens with flawed response, says damning report
By Harriet Marsden, The Week UK Published
-
The US is at risk for dengue fever
The explainer The buzz surrounding the mosquito-borne illness
By Devika Rao, The Week US Published